Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Viking Therapeutics (VKTX) Return on Equity (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Return on Equity for 12 consecutive years, with 0.83% as the latest value for Q1 2026.

  • For Q1 2026, Return on Equity fell 68.0% year-over-year to 0.83%; the TTM value through Mar 2026 reached 0.83%, down 68.0%, while the annual FY2025 figure was 0.47%, 29.0% down from the prior year.
  • Return on Equity hit 0.83% in Q1 2026 for Viking Therapeutics, down from 0.53% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.1% in Q2 2024 and bottomed at 0.83% in Q1 2026.
  • Average Return on Equity over 5 years is 0.31%, with a median of 0.28% recorded in 2023.
  • Year-over-year, Return on Equity skyrocketed 37bps in 2024 and then crashed -68bps in 2026.
  • Viking Therapeutics' Return on Equity stood at 0.46% in 2022, then soared by 48bps to 0.24% in 2023, then skyrocketed by 49bps to 0.12% in 2024, then plummeted by -333bps to 0.53% in 2025, then tumbled by -56bps to 0.83% in 2026.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.83%, 0.53%, and 0.31% for Q1 2026, Q4 2025, and Q3 2025 respectively.